# The Chemists Behind Ozempic's Rise
Thomas Kruse and Jesper Lau, two chemists working at Novo Nordisk, created semaglutide, the active ingredient in Ozempic. Their work fundamentally altered the landscape of weight management and metabolic disease treatment.
Semaglutide functions as a glucagon-like peptide-1 (GLP-1) receptor agonist. The drug mimics a natural hormone that regulates blood sugar and appetite signals in the brain. When injected weekly, semaglutide slows stomach emptying, increases feelings of fullness, and reduces hunger cravings. This mechanism explains why users often experience substantial weight loss alongside improved blood sugar control.
The development of semaglutide built on decades of research into incretin hormones. Novo Nordisk scientists recognized that a synthetic version of GLP-1 could offer therapeutic benefits beyond diabetes management. Their chemical innovations made the compound stable enough to survive digestion and remain active in the body long enough for weekly dosing, rather than requiring multiple daily injections.
Kruse and Lau's creation emerged from rigorous pharmaceutical development. Clinical trials demonstrated semaglutide's effectiveness for weight management in people with obesity, leading to FDA approval of Ozempic for type 2 diabetes in 2017 and Wegovy for chronic weight management in 2021.
The drug's popularity exploded following celebrity endorsements and social media discussions. Patients and physicians recognized semaglutide offered a pharmaceutical option for weight loss, addressing a gap where lifestyle interventions alone proved insufficient for many people. The medication becomes particularly valuable for individuals with metabolic syndrome, prediabetes, or heart disease risk factors alongside obesity.
However, semaglutide use carries considerations. Side effects include nausea,